US 11,866,485 B2
Antibody specific to spike protein of SARS-CoV-2 and uses thereof
Kuo-I Lin, Taipei (TW); Che Ma, New Taipei (TW); Chi-Huey Wong, Taipei (TW); Szu-Wen Wang, Taipei (TW); Yi-Hsuan Chang, Taichung (TW); Xiaorui Chen, Taipei (TW); and Han-Yi Huang, Taoyuan (TW)
Assigned to ACADEMIA SINICA, Taipei (TW)
Filed by ACADEMIA SINICA, Taipei (TW)
Filed on Oct. 3, 2022, as Appl. No. 17/937,744.
Claims priority of provisional application 63/251,472, filed on Oct. 1, 2021.
Prior Publication US 2023/0105209 A1, Apr. 6, 2023
Int. Cl. C07K 16/10 (2006.01); A61K 39/42 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/10 (2013.01) [A61K 39/42 (2013.01); A61K 2039/505 (2013.01); C07K 2317/14 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/34 (2013.01); C07K 2317/41 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 16 Claims
 
1. An antibody or antigen-binding fragment thereof that is specific for an epitope in a spike protein of a CoV; wherein the epitope comprises a part locating in 419 to 433 amino acid residues or 471 to 482 amino acid residues of SEQ ID NO: 8,
wherein the antibody or antigen-binding fragment thereof comprises complementarity determining regions (CDRs) of a heavy chain variable region and complementarity determining regions of a light chain variable region, wherein the complementarity determining regions of the heavy chain variable region comprise CDRH1, CDRH2, and CDRH3 regions, and the complementarity determining regions of the light chain variable region comprise CDRL1, CDRL2, and CDRL3 regions,
wherein the CDRH1 region comprises the amino acid sequence of SEQ ID NO: 1; the CDRH2 region comprises the amino acid sequence of SEQ ID NO: 2; the CDRH3 region comprises the amino acid sequence of SEQ ID NO: 3; and
the CDRL1 region comprises the amino acid sequence of SEQ ID NO: 4; the CDRL2 region comprises the amino acid sequence of WAS; the CDRL3 region comprises the amino acid sequence of SEQ ID NO: 5.